Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2021—Qiagen and Inovio Pharmaceuticals announced an extension of their partnership with a new agreement to develop liquid-biopsy–based companion diagnostic products based on next-generation sequencing technology to complement Inovio’s therapies.
July 2021—Diazyme launched its FDA 510(k)–exempt Beta-Hydroxybutyrate Assay for the quantitative determination of beta-hydroxybutyrate. BHB serves as a guide for monitoring the progress of insulin therapy for diabetic ketoacidosis and for patients presenting to the emergency room with documented hypoglycemia, acidosis, alcohol ingestion, or an unexplained increase in the anion gap.
July 2021—Bio-Rad Laboratories launched SARS-CoV-2 variant RT-PCR assays for research use only. The assays can detect SARS-CoV-2 variants of concern, including P.1, B.1.351, and B.1.1.7, by distinguishing specific mutations in SARS-CoV-2 using reverse transcription PCR, often prior to a next-generation–sequencing workflow for confirmation.
July 2021—The SML Genetree Sciences’ Ezplex SARS-CoV-2 G Kit has been granted FDA emergency use authorization. This is a real-time PCR in vitro diagnostic test for the qualitative detection of nucleic acid for SARS-CoV-2 RdRp and N genes from nasopharyngeal and oropharyngeal swabs and sputum specimens. The test can also be used for up to five pooled individual nasopharyngeal or oropharyngeal swabs. Testing of the FDA SARS-COV-2 Reference Panel showed a detection limit of 1,200 NAAT detectable units (NDU)/mL.
July 2021—Qiagen announced FDA emergency use authorization for the NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay, to help identify and differentiate people suspected of respiratory viral infection consistent with COVID-19.
July 2021—Roche launched eight configurations for its Cobas Pro integrated solutions, in countries accepting the CE mark. As a result, the analyzer can deliver up to 4,400 tests per hour, doubling its previous testing capacity. It is now possible to add two analytical units of Cobas c 503 and/or Cobas e 801, consolidating up to four analytical units on one platform.
July 2021—Thermo Fisher Scientific launched its CE-IVD-marked TaqPath COVID-19 Fast PCR Combo Kit 2.0. The kit uses an advanced assay design that compensates for current and emerging variants, the company says, by using eight targets across three genomic regions of the virus to help ensure the test provides accurate results even as the virus mutates.
July 2021—Beckman Coulter launched its Access SARS-CoV-2 IgG (1st IS), a fully quantitative lab-based immunoglobulin G serology test that measures the quantity of antibodies against the virus that causes COVID-19. The assay is traceable to the First WHO International Standard for anti-SARS-CoV-2, 20/136, and reports results aligned with BAU/mL established by the World Health Organization.
July 2021—Verichem Laboratories announced the availability of ready-to-use, liquid-stable clinical reference materials for the calibration and calibration verification of clinical testing systems.
July 2021—Sysmex America has added the FDA-cleared XN-10 Automated Hematology Analyzer with Blood Bank mode to its portfolio of hematology solutions. The analyzer supports red blood cell and platelet component testing and provides an automated complete blood count with differential for whole blood samples. The XN blood bank mode is intended for use in blood processing centers for QC release testing of post-processed components.
